SHPH Surges After Hours, Crosses Above 5-Day SMA

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: 21 Nov 25

Source: Benzinga

Shares of Shuttle Pharmaceuticals Holdings Inc. (SHPH.O) experienced a notable rebound in after-hours trading, surging 27.87% to $2.34, following a regular session decline of 7.58% to $1.83. This significant after-hours movement has propelled the stock above its 5-day simple moving average (SMA), indicating a potential shift in momentum.

The recent volatility comes on the heels of the company's filing of a Form S-1 registration statement with the SEC, aimed at the resale of 625,156 common shares linked to a pre-funded warrant. Additionally, Shuttle Pharmaceuticals successfully completed a private placement on November 4, raising approximately $2.5 million in gross proceeds, which may have bolstered investor confidence despite the stock's year-to-date decline of 91.4%.

With a current market capitalization of $2.93 million and 1,603,285 outstanding shares, the stock's recent performance highlights a critical juncture for investors as it navigates through a challenging market landscape.

SHPH

$2.19+Infinity%1D

Analyst Views on SHPH

About SHPH

Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

SHPH Surges After Hours, Crosses Above 5-Day SMA

Analyst Views on SHPH

About SHPH

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Microsoft Loses $357 Billion in Market Cap Amid Selling Frenzy

LCNB Reports Record Net Income of $23.1 Million for 2025

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch